Treatment with intravenous low-molecular-weight iron dextran (LMWID) seems to be an effective alternative for patients with nondialysis chronic kidney disease (ND-CKD) who remain anemic despite ...

July 2, 2010 (Munich, Germany) — The reported rates of adverse events (AE) from all intravenous (IV) iron products have increased in North America and Europe since 2002. The use of the products has ...

All iron intravenous (IV) products are associated with anaphylaxis risk, but the risk with iron dextran is significantly higher than with other formulations, and the risk is lowest with iron sucrose, ...

A single dose of intravenous (IV) iron dextran is the cost-effective treatment for women with heavy menstrual bleeding and iron deficiency anemia (IDA), according to new research published in Blood ...

IV iron dextran was the most cost-effective treatment, yielding 19.26 quality-adjusted life years at a cost of $157,500 vs 19.10 costing $152,900 for oral ferrous sulfate. HealthDay News — Intravenous ...

A single dose of intravenous (IV) iron dextran is the most cost-effective treatment for women with heavy menstrual bleeding and iron deficiency anemia (IDA), according to new research published in ...

For a monthly blood loss of 420 mL, the cost was $174,400 with IV iron dextran compared with $157,000 with oral ferrous sulfate, and the effectiveness was 18.91 and 17.19, respectively. The use of ...

Please provide your email address to receive an email when new articles are posted on . Iron dextran appeared to carry the greatest risk for anaphylaxis at first exposure of all marketed IV iron ...

Intravenous (IV) iron use overall is associated with a “very low” risk for anaphylaxis, but iron dextran and ferumoxytol carry an increased risk relative to iron sucrose, according to new research.

Experts highlight that IV iron not only helps combat anemic symptoms like fatigue and shortness of breath, but also significantly enhances women’s overall well-being. Unlike daily supplements, the ...

IV iron dextran is most cost-effective, yielding 19.26 QALYs compared with 19.10 QALYs for oral ferrous sulfate. (HealthDay News) — Intravenous (IV) iron dextran is the most cost-effective strategy ...